These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8017778)

  • 1. Cellular activation of thromboxane receptors.
    Kinsella BT; O'Mahony D; Lawson JA; Pratico D; Fitzgerald GA
    Ann N Y Acad Sci; 1994 Apr; 714():270-8. PubMed ID: 8017778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
    Yin K; Halushka PV; Yan YT; Wong PY
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha.
    Krauss AH; Woodward DF; Gibson LL; Protzman CE; Williams LS; Burk RM; Gac TS; Roof MB; Abbas F; Marshall K; Senior J
    Br J Pharmacol; 1996 Mar; 117(6):1171-80. PubMed ID: 8882612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular signaling by 8-epi-prostaglandin F2 alpha is mediated by thromboxane A2/prostaglandin endoperoxide receptors in porcine carotid arteries.
    Mohler ER; Franklin MT; Adam LP
    Biochem Biophys Res Commun; 1996 Aug; 225(3):915-23. PubMed ID: 8780711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of nonprostanoid trimetoquinol analogs with thromboxane A2/prostaglandin H2 receptors in human platelets, rat vascular endothelial cells and rat vascular smooth muscle cells.
    Shin Y; Romstedt KJ; Miller DD; Feller DR
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1017-23. PubMed ID: 7903383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells.
    Fukunaga M; Makita N; Roberts LJ; Morrow JD; Takahashi K; Badr KF
    Am J Physiol; 1993 Jun; 264(6 Pt 1):C1619-24. PubMed ID: 8333509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of prostaglandins and thromboxane A2 on coronary vessel tone--mechanisms of action and therapeutic implications.
    Schrör K
    Eur Heart J; 1993 Nov; 14 Suppl I():34-41. PubMed ID: 7507439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboxanes: synthase and receptors.
    Shen RF; Tai HH
    J Biomed Sci; 1998; 5(3):153-72. PubMed ID: 9678486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboxane A2/prostaglandin H2 receptor antagonists. A new therapeutic principle.
    Patscheke H
    Stroke; 1990 Dec; 21(12 Suppl):IV139-42. PubMed ID: 2148033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetyl glycerylphosphorylcholine aggregates human platelets through two distinct pathways, both dependent on arachidonic acid metabolism.
    Macconi D; Morzenti G; Livio M; Morelli C; Cassina G; Remuzzi G
    Lab Invest; 1985 Feb; 52(2):159-68. PubMed ID: 3155816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.
    Fitzgerald DJ; Doran J; Jackson E; FitzGerald GA
    J Clin Invest; 1986 Feb; 77(2):496-502. PubMed ID: 3003161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
    Lumley P; White BP; Humphrey PP
    Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Point mutation in the seventh hydrophobic domain of the human thromboxane A2 receptor allows discrimination between agonist and antagonist binding sites.
    Funk CD; Furci L; Moran N; Fitzgerald GA
    Mol Pharmacol; 1993 Nov; 44(5):934-9. PubMed ID: 8246916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosynthesis and pharmacological modulation of thromboxane in humans.
    Patrono C
    Circulation; 1990 Jan; 81(1 Suppl):I12-5; discussion I22-3. PubMed ID: 2136814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
    Vezza R; Mezzasoma AM; Venditti G; Gresele P
    Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
    Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
    Br J Pharmacol; 1993 Dec; 110(4):1600-6. PubMed ID: 8306107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular activation by thromboxane A2 and other eicosanoids.
    Reilly M; Fitzgerald GA
    Eur Heart J; 1993 Dec; 14 Suppl K():88-93. PubMed ID: 8131796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha.
    Kinsella BT; O'Mahony DJ; Fitzgerald GA
    J Pharmacol Exp Ther; 1997 May; 281(2):957-64. PubMed ID: 9152406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular activation by thromboxane A2 and 8-EPI-PGF2 alpha.
    Pratico D; O'Mahony D; Lawson J; Kinsella T; Fitzgerald GA
    Adv Exp Med Biol; 1997; 400A():229-33. PubMed ID: 9547562
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.